• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Carrier-Mediated Prodrug Uptake to Improve the Oral Bioavailability of Polar Drugs: An Application to an Oseltamivir Analogue

tetano

Editor, Senior Moderator
J Pharm Sci. 2016 Feb;105(2):925-34. doi: 10.1016/j.xphs.2015.11.036.
[h=1]Carrier-Mediated Prodrug Uptake to Improve the Oral Bioavailability of Polar Drugs: An Application to an Oseltamivir Analogue.[/h] Incecayir T[SUP]1[/SUP], Sun J[SUP]2[/SUP], Tsume Y[SUP]2[/SUP], Xu H[SUP]2[/SUP], Gose T[SUP]3[/SUP], Nakanishi T[SUP]3[/SUP], Tamai I[SUP]3[/SUP], Hilfinger J[SUP]4[/SUP], Lipka E[SUP]4[/SUP], Amidon GL[SUP]5[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] The goal of this study was to improve the intestinal mucosal cell membrane permeability of the poorly absorbed guanidino analogue of a neuraminidase inhibitor, oseltamivir carboxylate (GOC) using a carrier-mediated strategy. Valyl amino acid prodrug of GOC with isopropyl-methylene-dioxy linker (GOC-ISP-Val) was evaluated as the potential substrate for intestinal oligopeptide transporter, hPEPT1 in Xenopus laevis oocytes heterologously expressing hPEPT1, and an intestinal mouse perfusion system. The diastereomers of GOC-ISP-Val were assessed for chemical and metabolic stability. Permeability of GOC-ISP-Val was determined in Caco-2 cells and mice. Diastereomer 2 was about 2 times more stable than diastereomer 1 in simulated intestinal fluid and rapidly hydrolyzed to the parent drug in cell homogenates. The prodrug had a 9 times-enhanced apparent permeability (Papp) in Caco-2 cells compared with the parent drug. Both diastereomer exhibited high effective permeability (Peff) in mice, 6.32 ? 3.12 and 5.20 ? 2.81 ? 10(-5) cm/s for diastereomer 1 and 2, respectively. GOC-ISP-Val was found to be a substrate of hPEPT1. Overall, this study indicates that the prodrug, GOC-ISP-Val, seems to be a promising oral anti-influenza agent that has sufficient stability at physiologically relevant pHs before absorption, significantly improved permeability via hPEPT1 and potentially rapid activation in the intestinal cells.
Copyright ? 2016 American Pharmacists Association?. Published by Elsevier Inc. All rights reserved.


[h=4]KEYWORDS:[/h] Caco-2 cells; absorption potential; active transport; cell culture; membrane transport and transporters; peptide transporters; permeability; prodrugs

PMID: 26869437 [PubMed - in process]
 
Back
Top Bottom